|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,804.00 DKK | +0.78% |
|
+0.08% | -11.00% |
| 04-15 | Nordic Equities in North America - Astra Zeneca Gains 0.9 Percent | FW |
| 04-14 | Genmab A/S Provides Net Sales of Darzalex Results for the First Quarter of 2026 | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Bio Therapeutic Drugs
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 17.31B | |||||
| 52.04B | |||||
| 46.83B | |||||
| 30.82B | - | ||||
| 25.82B | - | ||||
| 19.66B |
- Stock Market
- Equities
- GMAB Stock
- Charts Genmab A/S
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition